AnaptysBio Inc (ANAB)

NASDAQ
27.21
-0.08(-0.29%)
  • Volume:
    38,903
  • Day's Range:
    26.41 - 27.48
  • 52 wk Range:
    18.20 - 37.89

ANAB Overview

Prev. Close
27.29
Day's Range
26.41-27.48
Revenue
52.9M
Open
27.05
52 wk Range
18.2-37.89
EPS
-3.9
Volume
38,903
Market Cap
767.54M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
270,417
P/E Ratio
-6.38
Beta
0.146
1-Year Change
-1.94%
Shares Outstanding
28,239,212
Next Earnings Date
Nov 10, 2022
What is your sentiment on AnaptysBio?
or
Vote to see community's results!

AnaptysBio Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

AnaptysBio Inc Analysis

AnaptysBio Inc Company Profile

AnaptysBio Inc Company Profile

Employees
102

AnaptysBio, Inc. is a clinical-stage biotechnology company developing immunology therapeutic product. The Company is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Read More

Analyst Price Target

Average36.20 (+33.04% Upside)
High50
Low23
Price27.21
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyBuyStrong BuyBuy
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyBuy
SummaryStrong BuyBuyStrong BuyStrong BuyBuy
  • HC Wainwright dropped their price objective on shares of Abeona Therapeutics from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, November 25th.
    0
    • Hi, I’m the second! Thinking to enter in this paper carefully.
      1
      • MY sweet Elena please do not do this . where are you from ? I am from Greece . You ? if you want to enter go to Vonage VG.
        0
      • you had right but now is late try to Vonage VG you will remember me if you will earn money come to Greece to visit me i am a Stock Consultant . Lefteris from Greece.
        0
    • I'm the first to comment! Lucky me!
      0